Literature DB >> 11483776

Noncytolytic inhibition of X4 virus by bulk CD8(+) cells from human immunodeficiency virus type 1 (HIV-1)-infected persons and HIV-1-specific cytotoxic T lymphocytes is not mediated by beta-chemokines.

R Geiben-Lynn1, M Kursar, N V Brown, E L Kerr, A D Luster, B D Walker.   

Abstract

Human immunodeficiency virus (HIV)-specific cytotoxic T lymphocytes (CTL) mediate immunologic selection pressure by both cytolytic and noncytolytic mechanisms. Non cytolytic mechanisms include the release of beta-chemokines blocking entry of R5 HIV-1 strains. In addition, CD8(+) cells inhibit X4 virus isolates via release of as yet poorly characterized soluble factors. To further characterize these factors, we performed detailed analysis of CTL as well as bulk CD8(+) T lymphocytes from six HIV-1-infected individuals and from six HIV-1-seronegative individuals. Kinetic studies revealed that secreted suppressive activities of HIV-1-specific CTL and bulk CD8(+) T lymphocytes from all HIV-1-infected persons are significantly higher than that of supernatants from seronegative controls. The suppressive activity could be blocked by monensin and brefeldin A, was heat labile, and appeared in a pattern different from that of secretion of chemokines (MDC, I-309, MIP-1alpha, MIP-1beta, and RANTES), cytokines (gamma interferon, tumor necrosis factor alpha, and granulocyte-macrophage colony-stimulating factor), and interleukins (interleukin-13 and interleukin-16). This suppression activity was characterized by molecular size exclusion centrifugation and involves a suppressive activity of >50 kDa which could be bound to heparin and a nonbinding inhibitory activity of <50 kDa. Our data provide a functional link between CD8(+) cells and CTL in the noncytolytic inhibition of HIV-1 and suggest that suppression of X4 virus is mediated through proteins. The sizes of the proteins, their affinity for heparin, and the pattern of release indicate that these molecules are not chemokines.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11483776      PMCID: PMC115075          DOI: 10.1128/jvi.75.17.8306-8316.2001

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  37 in total

1.  Cutting edge: naive T cells masquerading as memory cells.

Authors:  K Murali-Krishna; R Ahmed
Journal:  J Immunol       Date:  2000-08-15       Impact factor: 5.422

2.  HIV-1 gag-specific cytotoxic T lymphocytes recognize multiple highly conserved epitopes. Fine specificity of the gag-specific response defined by using unstimulated peripheral blood mononuclear cells and cloned effector cells.

Authors:  R P Johnson; A Trocha; L Yang; G P Mazzara; D L Panicali; T M Buchanan; B D Walker
Journal:  J Immunol       Date:  1991-09-01       Impact factor: 5.422

3.  Characterization of a 90-100 kDa tumor-associated antigen in the sera of melanoma patients.

Authors:  D M Euhus; R K Gupta; D L Morton
Journal:  Int J Cancer       Date:  1990-06-15       Impact factor: 7.396

4.  CD8(+)-Cell antiviral factor activity is not restricted to human immunodeficiency virus (HIV)-specific T cells and can block HIV replication after initiation of reverse transcription.

Authors:  S Le Borgne; M Février; C Callebaut; S P Lee; Y Rivière
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

5.  An activated CD8+ T cell phenotype correlates with anti-HIV activity and asymptomatic clinical status.

Authors:  A L Landay; C E Mackewicz; J A Levy
Journal:  Clin Immunol Immunopathol       Date:  1993-10

6.  Enhanced inhibition of human immunodeficiency virus type 1 by Met-stromal-derived factor 1beta correlates with down-modulation of CXCR4.

Authors:  O O Yang; S L Swanberg; Z Lu; M Dziejman; J McCoy; A D Luster; B D Walker; S H Herrmann
Journal:  J Virol       Date:  1999-06       Impact factor: 5.103

7.  Patients with HIV infection have a reduced proportion of lymphocytes expressing the IL2 receptor p55 chain (TAC, CD25).

Authors:  H Zola; L Y Koh; B X Mantzioris; D Rhodes
Journal:  Clin Immunol Immunopathol       Date:  1991-04

8.  CD8+ lymphocytes can control HIV infection in vitro by suppressing virus replication.

Authors:  C M Walker; D J Moody; D P Stites; J A Levy
Journal:  Science       Date:  1986-12-19       Impact factor: 47.728

9.  Long-term culture and fine specificity of human cytotoxic T-lymphocyte clones reactive with human immunodeficiency virus type 1.

Authors:  B D Walker; C Flexner; K Birch-Limberger; L Fisher; T J Paradis; A Aldovini; R Young; B Moss; R T Schooley
Journal:  Proc Natl Acad Sci U S A       Date:  1989-12       Impact factor: 11.205

10.  Interleukin 13 inhibits human immunodeficiency virus type 1 production in primary blood-derived human macrophages in vitro.

Authors:  L J Montaner; A G Doyle; M Collin; G Herbein; P Illei; W James; A Minty; D Caput; P Ferrara; S Gordon
Journal:  J Exp Med       Date:  1993-08-01       Impact factor: 14.307

View more
  17 in total

1.  Initial HIV-1 antigen-specific CD8+ T cells in acute HIV-1 infection inhibit transmitted/founder virus replication.

Authors:  Stephanie A Freel; Ralph A Picking; Guido Ferrari; Haitao Ding; Christina Ochsenbauer; John C Kappes; Jennifer L Kirchherr; Kelly A Soderberg; Kent J Weinhold; Coleen K Cunningham; Thomas N Denny; John A Crump; Myron S Cohen; Andrew J McMichael; Barton F Haynes; Georgia D Tomaras
Journal:  J Virol       Date:  2012-04-18       Impact factor: 5.103

2.  Novel function of prothymosin alpha as a potent inhibitor of human immunodeficiency virus type 1 gene expression in primary macrophages.

Authors:  Arevik Mosoian; Avelino Teixeira; Anthony A High; Robert E Christian; Donald F Hunt; Jeffrey Shabanowitz; Xinyan Liu; Mary Klotman
Journal:  J Virol       Date:  2006-09       Impact factor: 5.103

3.  Secretion of MIP-1β and MIP-1α by CD8(+) T-lymphocytes correlates with HIV-1 inhibition independent of coreceptor usage.

Authors:  Kevin O Saunders; Cavin Ward-Caviness; Robert J Schutte; Stephanie A Freel; R Glenn Overman; Nathan M Thielman; Coleen K Cunningham; Thomas B Kepler; Georgia D Tomaras
Journal:  Cell Immunol       Date:  2010-10-27       Impact factor: 4.868

Review 4.  The CD8+ T Cell Noncytotoxic Antiviral Responses.

Authors:  Maelig G Morvan; Fernando C Teque; Christopher P Locher; Jay A Levy
Journal:  Microbiol Mol Biol Rev       Date:  2021-05-12       Impact factor: 11.056

5.  Prothymosin-alpha inhibits HIV-1 via Toll-like receptor 4-mediated type I interferon induction.

Authors:  Arevik Mosoian; Avelino Teixeira; Colin S Burns; Leif E Sander; G Luca Gusella; Cijiang He; J Magarian Blander; Paul Klotman; Mary E Klotman
Journal:  Proc Natl Acad Sci U S A       Date:  2010-05-17       Impact factor: 11.205

Review 6.  CD8+ T cell control of HIV--a known unknown.

Authors:  Miles P Davenport; Janka Petravic
Journal:  PLoS Pathog       Date:  2010-01-29       Impact factor: 6.823

7.  Epigenetic regulation of CD8(+) T-lymphocyte mediated suppression of HIV-1 replication.

Authors:  Kevin O Saunders; Stephanie A Freel; R Glenn Overman; Coleen K Cunningham; Georgia D Tomaras
Journal:  Virology       Date:  2010-07-01       Impact factor: 3.616

8.  Induction of protective immune responses against R5 human immunodeficiency virus type 1 (HIV-1) infection in hu-PBL-SCID mice by intrasplenic immunization with HIV-1-pulsed dendritic cells: possible involvement of a novel factor of human CD4(+) T-cell origin.

Authors:  Atsushi Yoshida; Reiko Tanaka; Tsutomu Murakami; Yoshiaki Takahashi; Yoshio Koyanagi; Masataka Nakamura; Mamoru Ito; Naoki Yamamoto; Yuetsu Tanaka
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

9.  CD8(+) lymphocytes suppress human immunodeficiency virus 1 replication by secreting type I interferons.

Authors:  M Scott Killian; Fernando Teque; Robert L Walker; Paul S Meltzer; J Keith Killian
Journal:  J Interferon Cytokine Res       Date:  2013-02-12       Impact factor: 2.607

10.  Anti-HSV activity of serpin antithrombin III.

Authors:  Debra C Quenelle; Tracy L Hartman; Robert W Buckheit; Mark N Prichard; Ralf Geiben Lynn
Journal:  Int Trends Immun       Date:  2014-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.